Gesynta Pharma: Funding, Investors & Team (Sep 2026)

Gesynta Pharma is a pharmaceutical company in the clinical testing stage that is developing a range of compounds that target the pro-inflammatory enzyme mPGES-1. The company's research is rooted in Karolinska Institutet. Their leading drug candidate, vipoglanstat (GS-248), is currently being developed as a non-hormonal treatment for endometriosis. In preclinical testing on endometriosis, vipoglanstat showed significant reductions in the number of lesions associated with the disease, as well as providing pain relief and improved well-being. Clinical studies have shown that vipoglanstat has a favorable safety profile and promising pharmacological properties, leading to preparations for a phase II study in patients with endometriosis. Endometriosis is a common, painful inflammatory disease that affects about 10% of women of reproductive age, with current treatment options often falling short. Gesynta Pharma, founded in 2017 and located in Stockholm, also has plans for another drug candidate, GS-073, to enter clinical testing in 2023 for a different inflammatory condition. Shareholders in the company include Hadean Ventures, Industrifonden, Linc, and a group of successful life science industry entrepreneurs.

Gesynta Pharma has raised $27.3M across 1 round on record. The most recent is a Series B of $27.3M announced in Jan 2025.

Gesynta Pharma's most recent funding round on record is a Series B of $27.3M, announced in Jan 2025.

FundedIQ lists Patric Stenberg (Founder) at Gesynta Pharma.

Gesynta Pharma is based in Stockholm, Stockholms Lan, Sweden.

Gesynta Pharma is in the 11-50 employee band.

Gesynta Pharma's latest round of $27.3M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.